Reviewing Bionano Genomics (NASDAQ:BNGO) & Telesis Bio (NASDAQ:DNAY)
Reviewing Bionano Genomics (NASDAQ:BNGO) & Telesis Bio (NASDAQ:DNAY)
Bionano Genomics (NASDAQ:BNGO – Get Rating) and Telesis Bio (NASDAQ:DNAY – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.
生物纳米基因(纳斯达克：bngo-Get Rating)和Telesis Bio(纳斯达克：DNAY-GET Rating)都是小盘医疗公司，但哪只股票更好？我们将根据这两家公司的股息、收益、盈利能力、机构所有权、风险、估值和分析师的建议来比较它们的实力。
Analyst Recommendations
分析师建议
This is a breakdown of recent ratings and target prices for Bionano Genomics and Telesis Bio, as reported by MarketBeat.com.
据MarketBeat.com报道，这是Bionano基因组公司和Telesis Bio公司最近的评级和目标价格细目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bionano Genomics | 0 | 0 | 2 | 0 | 3.00 |
| Telesis Bio | 0 | 0 | 2 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 生物纳米基因组学 | 0 | 0 | 2 | 0 | 3.00 |
| Telesis Bio | 0 | 0 | 2 | 0 | 3.00 |
Bionano Genomics presently has a consensus target price of $7.75, indicating a potential upside of 409.87%. Telesis Bio has a consensus target price of $5.00, indicating a potential upside of 303.23%. Given Bionano Genomics' higher probable upside, research analysts clearly believe Bionano Genomics is more favorable than Telesis Bio.
生物纳米基因组公司目前的共识目标价为7.75美元，这表明潜在的上涨幅度为409.87%。Telesis Bio的共识目标价为5美元，表明潜在上涨303.23%。考虑到Bionano基因组学更有可能的上行空间，研究分析师显然认为Bionano基因组学比Telesis Bio更有利。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Bionano Genomics | -451.42% | -38.48% | -34.11% |
| Telesis Bio | -251.04% | -73.65% | -51.19% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 生物纳米基因组学 | -451.42% | -38.48% | -34.11% |
| Telesis Bio | -251.04% | -73.65% | -51.19% |
Insider and Institutional Ownership
内部人与机构持股
26.9% of Bionano Genomics shares are held by institutional investors. Comparatively, 42.7% of Telesis Bio shares are held by institutional investors. 1.2% of Bionano Genomics shares are held by company insiders. Comparatively, 30.2% of Telesis Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Bionano基因公司26.9%的股份由机构投资者持有。相比之下，Telesis Bio 42.7%的股份由机构投资者持有。Bionano基因公司1.2%的股份由公司内部人士持有。相比之下，Telesis Bio 30.2%的股份由公司内部人士持有。强大的机构持股表明，大型基金管理公司、捐赠基金和对冲基金相信，一只股票的长期表现将好于大盘。
Valuation and Earnings
估值和收益
This table compares Bionano Genomics and Telesis Bio's gross revenue, earnings per share (EPS) and valuation.
该表格比较了Bionano Genonics和Telesis Bio的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bionano Genomics | $17.98 million | 25.10 | -$72.43 million | ($0.41) | -3.71 |
| Telesis Bio | $11.04 million | 3.32 | -$38.96 million | ($1.80) | -0.69 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 生物纳米基因组学 | 1,798万美元 | 25.10 | -7243万美元 | ($0.41) | -3.71 |
| Telesis Bio | 1104万美元 | 3.32 | -3,896万元 | ($1.80) | -0.69 |
Telesis Bio has lower revenue, but higher earnings than Bionano Genomics. Bionano Genomics is trading at a lower price-to-earnings ratio than Telesis Bio, indicating that it is currently the more affordable of the two stocks.
Telesis Bio的收入较低，但收益高于Bionano基因组公司。生物纳米基因组公司的市盈率低于Telesis Bio，这表明它目前是两只股票中更负担得起的一只。
Volatility & Risk
波动性与风险
Bionano Genomics has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Comparatively, Telesis Bio has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500.
BioNano Genonics的贝塔系数为2.15，表明其股价的波动性比标准普尔500指数高出115%。相比之下，Telesis Bio的贝塔系数为1.38，这表明其股价的波动性比标准普尔500指数高38%。
Summary
摘要
Bionano Genomics beats Telesis Bio on 7 of the 12 factors compared between the two stocks.
在两只股票之间的12个因素中，生物纳米基因组学在7个因素上击败了Telesis Bio。
About Bionano Genomics
关于Bionano基因组学
(Get Rating)
(获取评级)
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
生物纳米基因组公司提供基因组分析软件解决方案。它提供了用于通过光学基因组图谱进行结构变异分析的样本到结果的解决方案，用于基因组分析和了解遗传变异和功能；SAHERR仪器，一个单分子成像仪；SETRUR芯片，一个包装用于DNA线性化的纳米通道阵列的消耗品；以及Bionano制备试剂盒和DNA标记试剂盒，它提供了提取和标记超高分子量的试剂和协议。该公司还提供Skerr和Bionano计算机服务器；以及NxClinic，该公司提供一个系统，用于分析和解释微阵列的基因组变异，以及细胞遗传学和分子遗传学的下一代测序数据。此外，它还提供检测和实验室服务，包括FirstStepDx plus，一个染色体微阵列，用于确定自闭症谱系障碍、发育迟缓和智力残疾的潜在遗传原因；脆性X综合征(FXS)测试服务；NextStepDx plus，一个外显子组测序测试，以确定与儿童发育障碍有关的基因变异；EpiPanelDx plus，为经历过癫痫、婴儿痉挛、脑病或发热性癫痫的患者提供基因测试小组；PGx测试，在11个基因中确定60多个等位基因。该公司成立于2003年，总部设在加利福尼亚州圣地亚哥。
About Telesis Bio
关于Telesis Bio
(Get Rating)
(获取评级)
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Codex DNA公司是一家合成生物学公司，主要向世界各地的制药和学术实验室制造和销售合成生物学仪器、试剂和相关产品及相关服务。它的解决方案包括BioXp系统，它使研究人员能够从数字DNA序列过渡到终端就绪的合成DNA；BioXp门户网站，它提供了直观的指导工作流程和设计工具，用于构建新的DNA序列并将其组装成选择的载体；BioXp试剂盒，其中包含用于特定合成生物学工作流程应用的构建块和试剂，包括其Gibson Assembly品牌试剂；基于云的脚本；Benchtop试剂，包含使用BioXp系统生成的产品在桌面上进行特定合成生物学工作流程所需的所有试剂；Biofoundry服务，使客户能够订购和接收BioXp系统终端就绪型产品，如基因、克隆、无细胞扩增DNA和变异库；以及短寡聚连接组装酶DNA合成。它还为政府机构、合同研究组织和合成生物学公司提供服务。该公司前身为SGI-DNA，Inc.，并于2020年3月更名为Codex DNA，Inc.。Codex DNA，Inc.成立于2011年，总部设在加利福尼亚州圣地亚哥。
Receive News & Ratings for Bionano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
获得Bionano基因组学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Bionano Genonics和相关公司的最新新闻和分析师评级的每日简要摘要。